Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE...

Full description

Saved in:
Bibliographic Details
Main Authors: Keneth Iceland, Kasozi, Simon Peter, Musinguzi
Format: Article
Language:English
Published: Frontiers in Public Health 2021
Subjects:
Online Access:http://hdl.handle.net/20.500.12493/471
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1800403076139450368
author Keneth Iceland, Kasozi
Simon Peter, Musinguzi
author_facet Keneth Iceland, Kasozi
Simon Peter, Musinguzi
author_sort Keneth Iceland, Kasozi
collection KAB-DR
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson’s disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-g (IFN-g), and tumor necrosis factor-a (TNF-a). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-kB), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A2 in the management of respiratory and neurological diseases. BV activation of the cellular and humoral immune systems should be explored for the application of complementary medicine for the management of SARS-CoV-2 infections. BV “vaccination” is used to immunize against cytomegalovirus and can suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate for complementary therapy for protection against SARS-CoV-2.
format Article
id oai:idr.kab.ac.ug:20.500.12493-471
institution KAB-DR
language English
publishDate 2021
publisher Frontiers in Public Health
record_format dspace
spelling oai:idr.kab.ac.ug:20.500.12493-4712024-01-17T04:49:27Z Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections Keneth Iceland, Kasozi Simon Peter, Musinguzi bee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV), pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trials Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson’s disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-g (IFN-g), and tumor necrosis factor-a (TNF-a). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-kB), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A2 in the management of respiratory and neurological diseases. BV activation of the cellular and humoral immune systems should be explored for the application of complementary medicine for the management of SARS-CoV-2 infections. BV “vaccination” is used to immunize against cytomegalovirus and can suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate for complementary therapy for protection against SARS-CoV-2. Kabale University 2021-01-25T06:48:00Z 2021-01-25T06:48:00Z 2020 Article Kasozi KI, Niedbała G, Alqarni M, Zirintunda G, Ssempijja F, Musinguzi SP, Usman IM, Matama K, Hetta HF, Mbiydzenyuy NE, Batiha GE-S, Beshbishy AM and Welburn SC (2020) Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. Front. Public Health 8:594458. doi: 10.3389/fpubh.2020.594458 http://hdl.handle.net/20.500.12493/471 en application/pdf Frontiers in Public Health
spellingShingle bee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV), pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trials
Keneth Iceland, Kasozi
Simon Peter, Musinguzi
Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title_full Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title_fullStr Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title_full_unstemmed Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title_short Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
title_sort bee venom a potential complementary medicine candidate for sars cov 2 infections
topic bee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV), pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trials
url http://hdl.handle.net/20.500.12493/471
work_keys_str_mv AT kenethicelandkasozi beevenomapotentialcomplementarymedicinecandidateforsarscov2infections
AT simonpetermusinguzi beevenomapotentialcomplementarymedicinecandidateforsarscov2infections